Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Cantor Fitzgerald
Federal Trade Commission

Generated: November 25, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,900,638

« Back to Dashboard

Which drugs does patent 8,900,638 protect, and when does it expire?

Patent 8,900,638 protects KAZANO and is included in one NDA. There has been one Paragraph IV challenge on Kazano.

This patent has twenty-nine patent family members in twenty-three countries.

Summary for Patent: 8,900,638

Title:Solid preparation comprising alogliptin and metformin hydrochloride
Abstract: The present invention provides a solid preparation containing compound (I) [compound (I) is as defined in the specification] or a salt thereof, and metformin hydrochloride, which is useful as a therapeutic drug for diabetes and the like, and superior in the preservation stability. A solid preparation having a first part and a second part: a first part: a part containing compound (I) or a salt thereof and substantially free of metformin hydrochloride a second part: a part containing metformin hydrochloride and substantially free of compound (I) and a salt thereof.
Inventor(s): Yamamoto; Kazumichi (Osaka, JP), Koyama; Hiroyoshi (Osaka, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:12/452,705
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Formulation; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Takeda Pharms Usa
alogliptin benzoate; metformin hydrochloride
TABLET;ORAL203414-002Jan 25, 2013RXYesYes► Subscribe► SubscribeY
Takeda Pharms Usa
alogliptin benzoate; metformin hydrochloride
TABLET;ORAL203414-001Jan 25, 2013RXYesNo► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,900,638

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2007-188574Jul 19, 2007
PCT Information
PCT FiledJuly 16, 2008PCT Application Number:PCT/JP2008/063228
PCT Publication Date:January 22, 2009PCT Publication Number: WO2009/011451

International Patent Family for Patent: 8,900,638

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Peru09232014► Subscribe
Peru08822009► Subscribe
New Zealand583346► Subscribe
Malaysia159203► Subscribe
Morocco31592► Subscribe
South Korea101536786► Subscribe
South Korea20100036367► Subscribe
Japan2014058547► Subscribe
Japan5479318► Subscribe
Japan2010533643► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Federal Trade Commission
Queensland Health
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus